Job Openings for Pharmacovigilance Scientist

Quantum Solutions India Job Openings for Pharmacovigilance Scientist:
Posted Date: 09 Jun 2012

How to Apply:
Interested and eligible candidate should need to, please write to us at hr@qsi.in quoting the relevant position code, until the job postsa re available on the website.

Employer Name: Quantum Solutions India
Employer Address: Quantum Solutions India DLF Building Tower D, 3rd Floor, Chandigarh Technology Park Chandigarh 160 101
Email: hr@qsi.in
URL: http://www.qsi.in/

Phone: NA

Required Skills: Fluency in written and spoken English, computer proficiency
Required Experience: Experience in the Pharmacovigilance industry would be an advantage. Good knowledge of medical terminology

Required Education: Master degree in Life Sciences (Pharmacy, Microbiology, Biochemistry, Biotechnology or Biophysics) or a degree in Medicine or Dentistry;
Job Location: Chandigarh, U.T., India.

How to Apply:

Interested and eligible candidate should need to, please write to us at hr@qsi.in quoting the relevant position code, until the job postsa re available on the website.

Read more »

Posted in: Pharma Jobs

Interview Call Letter-Cadila Pharmaceuticals Limited

Interview Call Letter- July Batch For Medical Representative_WEST ZONE
by Cadila Pharmaceuticals Limited in Mumbai, Jaipur, Raipur, Bhopal, Ahmedabad, Pune
Experience: 0 to 1 yrs. Posted on: 11 Jun

JD:
Dear Candidate,
IRM LTD as a member of Cadila Group Companies has embarked upon major initiative by way of launching its Centre of Professional Excellence (CPEX) , which is India’s only Pharmaceutical Training Academy providing Professional Certification Course and Guarantee of Job to meet the manpower requirements for current as well as future expansion of the branded business of Cadila Pharmaceuticals Ltd.

STIPEND:
During training period, you will be paid Rs. 6000.00 each month end towards Stipend and Conveyance Allowance (During Field Training).

EMPLOYMENT AND COMPENSATION:
• Salary: After certification you will be deployed by Cadila Pharmaceuticals on regular employment with CTC of Rs.1,10,000.00 (for non-metro cities) per annum or with CTC Rs. 1,30,000 (Metro cities) per annum.

• Daily Working Allowances: As Field Officer, you will also be eligible for Daily Allowances (DA) based upon the area covered. Cadila Pharmaceuticals pays average DA between Rs. 4000 to 4500 per month.

• Lucrative Incentives: Cadila Pharmaceuticals also encourages performing Field Officers by offering performance linked incentives. The scope of earning yearly incentives ranges between Rs. 20000 to 25000.

• Retention Bonus: Cadila Pharmaceuticals will pay you a retention bonus of Rs. 7000 at the time of Performance Appraisal of second year in your job.

Agreement: The candidate would be deployed by Cadila Pharmaceuticals on regular employment for an agreement of minimum 2 years.

Note: (Please read this members)

As you can understand, CPEX will incur certain cost while providing you this vocational training. After you are deployed on the job with Cadila Pharmaceuticals, we will recover a cost of Rs. 25000/- in 12 equal monthly installments from the salary.

Nature of Job: Medical Representative
Minimum Qualification: B. Pharma / D. Pharma / BBA / B. Sc / B. Com / BA
Age Criteria: Upto 25 Years
Job Location: Anywhere in India
Note: Bike / Two Wheeler are must for this position.

Contact Details
Executive Name:Ms. Vinita Sharma
Contact Company:Cadila Pharmaceuticals Limited
Address: Cadila Corporate Campus Sarkhej - Dholka Road, Bhat, AHMEDABAD,Gujarat,India 382210
Email Address:vinita.sharma@cadilapharma.co.in,deshna.shah@cadilapharma.co.in
Telephone:9979863978

Read more »

Posted in: Pharma Jobs

Do you know what are top 10 Best-selling Cancer Drugs

Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development, as the upcoming American Society of Clinical Oncology meeting will attest. The usual reasons for growing drug demand apply: Rising healthcare spending in countries such as China; an expanding middle class better able to access healthcare in India and other emerging markets; and aging populations in big drug markets like the U.S. and Japan.

But cancer drugs have their own unique drivers. They treat deadly, frightening diseases, so patients demand them, even at nosebleed prices. Penny-pinching gatekeepers like the U.K.'s National Institute for Health and Clinical Excellence are more amenable to new drugs for patients with terminal illness, if not at pharma's asking price.

Many of the newer cancer drugs, recently approved and in development, are aimed at cancers with specific genetic variations, so the drugs can be targeted to patients who are most likely to benefit--and that likely benefit can command premium prices. Finally, biologic treatments for cancer don't face generic competition on schedule as traditional drugs do, so even older drugs such as Herceptin don't have to contend with low-cost knockoffs. U.S. provisions for biosimilar versions guarantee that will change--but it hasn't changed yet.

In fact, the three top-selling cancer drugs on our list--Rituxan, Avastin and Herceptin--were approved in 1997, 2004, and 1998, respectively. So, they've been long-term earners for their developer, Genentech, now Roche's ($RHHBY) U.S. unit. The newest drug on the list is Tarceva, another Genentech product, which won FDA approval in November 2004.

So, let's get down to the figures: These 10 treatments brought in U.S. sales last year ranging from $564 million to $3 billion, according to IMS Health numbers. Our Nesa Nourmohammadi gathered the data

Rituxan - $3 billion

Avastin - $2.66 billion

Herceptin - $1.66 billion

Gleevec - $1.51 billion

Eloxatin - $1.2 billion

Alimta - $1.04 billion

Erbitux - $703.3 million

Velcade - $692.7 million

Xeloda - $647.6 million

Tarceva - $564.2 million

Read more »

Posted in: My reviews